Navigation Links
BioSpec Global Solutions Inc, takes delivery of new TOG's 3000 Home edition for the U.S. and international markets
Date:2/1/2010

NEW YORK and MONTREAL, Feb. 1 /PRNewswire-FirstCall/ - ICBS Ltd. (OTCPK: ICBT), announced today that it has taken delivery of the new TOGS(TM) 3000 bio-photonic incubation & detection systems, which the company will be marketing in the U.S. and overseas. The TOGS(TM) 3000 has 100% accuracy in the detection of Total Coli forms and E. Coli bacteria in water.

"BioSpec Global Solutions will be moving to introduce the new TOGS(TM) 3000 in the U.S, and overseas." said Don Saunders, President and CEO. "Given the advantages on processing time (24 hours) plus the accuracy of these machines, (100%), can equip people with the technology needed to insure safe drinking water ."

The TOGS(TM) 3000 has been verified by Ryerson University, Agriculture Canada and Saskatchewan Department of Health. It has been accepted for use for drinking water analysis by EPA in the USA when used in conjunction with our EPA approved reagent and method,. The TOGS(TM) 3000 has been used in a research project by the World Health Organization in Hawaii and by OCETA in India. Agents and distributors are being established to set up a global marketing network. Further verification and validation studies will be done shortly by users and ETV (Environmental Technology Verification) for microbial quantification for beach and wastewater applications.

The timing for commercialization is excellent. The World Health Organization has declared "safe drinking water is a human right" and the United Nations is struggling with its mandate to protect drinking water quality in over 100 million wells worldwide. Governments of the world are being pressured to conform to these directives. World pressure on China over food and water safety is presently a good example of that. BioSpec Global Solutions is currently in talks with a Chinese distributor.

The company holds worldwide patents on the TOGS(TM) 3000 and TOGS9000.(TM)

NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.

SOURCE BioSpec Global Solutions Inc.


'/>"/>
SOURCE BioSpec Global Solutions Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC
2. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
3. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
4. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
5. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
6. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
7. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
8. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
9. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
10. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
11. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent ... entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 ... joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
Breaking Biology Technology:
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
Breaking Biology News(10 mins):